Rahul Agrawal Snapshot

Cereno Scientific AB is a clinical-stage biotech company that develops treatments for cardiovascular diseases,Cereno Scientific develops treatments for rare and common cardiovascular diseases, including those with thrombosis, fibrosis, high pressure, and inflammation.

Cereno Scientific's B share (CRNO B) has been traded on Nasdaq First North Growth Market since June 2023.

Cereno Scientific's headquarters are in AstraZeneca's BioVenture Hub in Sweden.

• Dr. Agarwal expressed his excitement about joining Cereno Scientific, highlighting the company’s promising drug candidate portfolio and platform aimed at transforming treatment for cardiovascular diseases.
• He noted that Cereno's focus on pulmonary arterial hypertension (PAH) and thrombosis prevention could lead to a significant shift in patient care.
• He emphasized the portfolio's potential for reverse remodelling in PAH and its ability to prevent thrombosis without the associated bleeding risks, which he considers highly clinically relevant.